Nature Communications · 2023 · 36 citations · 28 references
Life SciencesImmunologyInfectious DiseasesImmunizationVaccine ImmunologyVaccinologyNanoparticle-based ImmunotechnologyNucleic Acid VaccinesVaccine DeliveryVaccine Delivery SystemsVaccine PlatformsViral VaccinesLipid NanoparticlesProtectionReceptor Binding Domain VaccinesSelf-amplifying Messenger RnaSelf-amplifying Ribonucleic Acid (Rna) VaccineSelf-amplifying Rna VaccinesTransmembrane DomainsVaccine Candidate Antigens
Several vaccines have been widely used to counteract the global pandemic caused by SARS-CoV-2. However, due to the rapid emergence of SARS-CoV-2 variants of concern (VOCs), further development of vaccines that confer broad and longer-lasting protection against emerging VOCs are needed. Here, we report the immunological characteristics of a self-amplifying RNA (saRNA) vaccine expressing the SARS-CoV-2 Spike (S) receptor binding domain (RBD), which is membrane-anchored by fusing with an N-terminal signal sequence and a C-terminal transmembrane domain (RBD-TM). Immunization with saRNA RBD-TM delivered in lipid nanoparticles (LNP) efficiently induces T-cell and B-cell responses in non-human primates (NHPs). In addition, immunized hamsters and NHPs are protected against SARS-CoV-2 challenge. Importantly, RBD-specific antibodies against VOCs are maintained for at least 12 months in NHPs. These findings suggest that this saRNA platform expressing RBD-TM will be a useful vaccine candidate inducing durable immunity against emerging SARS-CoV-2 strains.
28
Enzymatic assembly of DNA molecules up to several hundred kilobases
Daniel G. Gibson, Lei Young, Ray-Yuan Chuang et al. · Nature Methods · 2009 · 10.9K citations
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Jun Lan, Jiwan Ge, Jinfang Yu et al. · Nature · 2020 · 6.7K citations · Full text